We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-48.93%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
AUM
$133M
AUM Growth
-$130M
Cap. Flow
-$1.73M
Cap. Flow %
-1.29%
Top 10 Hldgs %
100%
Holding
2
New
Increased
Reduced
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$1.73M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TXG icon
1
10x Genomics
TXG
$5.83B
$133M 100%
1,753,528
EPZM
2
DELISTED
Epizyme, Inc
EPZM
-690,002
Closed -$1.73M

Similar funds

Foresite Capital Management II's Q1 2022 Portfolio in Review

As of Q1 2022, Foresite Capital Management II held 2 positions worth $133M, down 49% from $263M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II's Q1 2022 filing shows 1 closed position. The largest sale was Epizyme, Inc, an estimated $1.73M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management II fully exited Epizyme, Inc in Q1 2022, selling an estimated $1.73M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $133M portfolio in Q1 2022.
  • Foresite Capital Management II opened 0 new positions and closed 1 in Q1 2022.
  • Foresite Capital Management II's portfolio value fell 49% quarter-over-quarter to $133M.

Based on Foresite Capital Management II's 13F filing for Q1 2022, filed 13 May 2022.